Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27388637 | 0.89 | HTR1A (0.55) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL3088462 | 0.82 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL31415056 | 0.82 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL1180288 | 0.82 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL6284658 | 0.82 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL15871971 | 0.82 | HTR1A (0.53) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL3411094 | 0.82 | HTR1A (0.50) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL4928212 | 0.82 | MAPT (0.55) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| Hydrochloric Acid SCHEMBL3092379 | 0.81 | HTR1A (0.49) | HTR1AADRA1DADRA1AADRA1BMEN1 | |
| SCHEMBL16207728 | 0.81 | ALDH1A1 (0.56) | HTR1AADRA1DADRA1AADRA1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2439193-B1 | Derivatives of 5,6-bisaryl-2-pyridine-carboxamide, preparation and use thereof in therapeutics as antagonists of urotensin II receptors | SANOFI SA (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8552201-B2 | 5, 6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI (FR) | 2013-10-08 | — | — | US | disclosed |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS | 2012-05-03 | — | — | US | disclosed |
| EP-2059508-B1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI SA (FR) | 2012-04-11 | — | — | EP | disclosed |
| US-8110579-B2 | 5,6-bisaryl-2-pyridine-carboxamide derivatives, preparation and application thereof in therapeutics as urotensin II receptor antagonists | SANOFI-AVENTIS (FR) | 2012-02-07 | — | — | US | disclosed |
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI AVENTIS | 2009-12-24 | — | — | US | disclosed |
| EP-2059508-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008020124-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318473-A1 | 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | HTR1A 390/4885ADRA1D 399/4885ADRA1A 372/4885 |
| US-20120108611-A1 | 5, 6-BISARYL-2-PYRIDINE-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS AS UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, NTSR2 | HTR1A 390/4885ADRA1D 399/4885ADRA1A 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.